Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06885424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Study acronym: DESCENT-1
StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 2 to 3 Start date changed from estimate of Aug 31, 2025 to Jul 31, 2025v3 Show 1 more changeShow less
    • Start date changed from estimate of Aug 31, 2025 to Jul 31, 2025
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation Site contacts updated at 1 of 2 sitesv2 Show 1 more changeShow less
    • Site contacts updated at 1 of 2 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A2 Biotherapeutics Inc.
5 trials monitored
See all monitored trials
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
and 8 more diseases
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Trial Details
NCT Number NCT06885424
Lead Sponsor A2 Biotherapeutics Inc.
Conditions Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC), Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Pancreatic Cancer, NSCLC +7 more
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov